<DOC>
	<DOCNO>NCT01415921</DOCNO>
	<brief_summary>Heart failure , common heart disease affect nearly 6 million Americans , associate high rate hospitalization death . Abnormalities autonomic nervous system think play important role progression heart failure . This proposal aim determine whether novel application pyridostigmine , drug currently approve FDA treatment neuromuscular disease , improve autonomic nervous system function heart failure patient .</brief_summary>
	<brief_title>Safety Study Pyridostigmine Heart Failure</brief_title>
	<detailed_description>Autonomic dysregulation cardiovascular system , characterize heighten sympathetic activity withdrawal parasympathetic activity promote progression heart failure . Pharmacological blockade sympathetic overactivity associate reduced mortality risk , data pharmacologic augmentation parasympathetic withdrawal . Acetylcholinesterase inhibitor augment parasympathetic neurotransmission block enzymatic breakdown acetylcholine cholinergic receptor site . Pyridostigmine short-acting , reversible acetylcholinesterase inhibitor approve FDA treatment myasthenia gravis . We propose Phase II prospective randomize , double-blind trial compare 12 week treatment ascend dos pyridostigmine ( 15 , 30 , 60 mg every 8 hour ) vs. match placebo 60 patient symptomatic chronic heart failure associate leave ventricular systolic dysfunction . The clinical pharmacology pyridostigmine investigate follow specific aim : 1 ) To characterize effect oral pyridostigmine vs. placebo sympathovagal balance patient chronic heart failure ; 2 ) To characterize safety tolerability oral pyridostigmine vs. placebo patient chronic heart failure ; 3 ) To characterize steady state pharmacokinetic pharmacodynamic property repeat oral dose pyridostigmine patient chronic heart failure . Mixed effect model use determine association study drug assignment physiological marker sympathovagal balance ( post-exercise heart rate recovery , heart rate variability , cardiovagal baroreceptor function , rest/exercise blood catecholamine level ) , descriptive statistic characterize safety/tolerability measure ( exercise capacity , quality life , biomarkers disease progression , cholinergic symptom score ) , population pharmacokinetic/pharmacodynamic modeling characterize relationship study dosing , study drug blood level , degree cholinesterase inhibition measure sympathovagal balance safety/tolerability . The overall goal characterize potential pyridostigmine novel treatment heart failure subject obtain information necessary evaluate feasibility/logistics future Phase III outcomes study heart failure patient . The proposed study provide new data critically need direct future development promise drug novel therapeutic approach reduction morbidity mortality heart failure patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Pyridostigmine Bromide</mesh_term>
	<criteria>Age 2175 year Symptomatic NYHA Class IIIII heart failure &gt; 6 month Left ventricular ejection fraction &lt; 35 % Previous implantation implantable cardiovertor defibrillator pacemaker Guidelinerecommended heart failure treatment &gt; 3 month Able willing provide write informed consent Contraindications cholinergic stimulation Heart failure primarily attributable genetic , valvular , infiltrative disease Persistent atrial fibrillation Sick sinus syndrome Pacemaker dependency exercise Severe chronotropic incompetence peak exercise heart rate &lt; 100 min1 Severe exercise intolerance ( unable complete first stage Bruce Protocol ) Coronary cerebral atherothrombotic event within past year Hospitalization emergency room visit heart failure within last 3 month ICD shock last 6 month Diabetes mellitus peripheral neuropathy Autonomic peripheral neuropathy cause Systolic blood pressure &lt; 90 &gt; 160 mmHg Resting heart rate &lt; 60 &gt; 100 min1 Serum sodium &lt; 132 mmol/L Serum creatinine &gt; 2.5 mg/dl Liver function test &gt; 3 time upper limit normal Severe anemia ( Hemoglobin &lt; 10 gm/dl ) FEV1.0 &lt; 60 % predict FEV1.0/FVC ratio &lt; 70 % PR interval &gt; 240 msec second third degree heart block electrocardiogram Exercise limit primarily angina noncardiac comorbid condition Pregnant breastfeed woman Current treatment medication know interact pyridostigmine Known intolerance oral preparation contain bromide Any condition ( e.g. , psychiatric illness active substance abuse ) situation , investigator 's opinion , may put subject significant risk , may confound study result , may interfere significantly subject 's ability adhere study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>heart failure</keyword>
	<keyword>autonomic function</keyword>
	<keyword>sympathovagal balance</keyword>
	<keyword>cholinesterase inhibitor</keyword>
	<keyword>pharmacology</keyword>
</DOC>